Neuroimaging Sleep and Mood in Depression
Identifying Brain Dynamics Underlying Sleep and Mood in Depression
1 other identifier
interventional
60
1 country
1
Brief Summary
This study will investigate how sleep and mood are related in patients with depression and in healthy controls. It will use MRI-based measures of brain function to determine how neural systems are modulated by sleep and sleep deprivation, and its links to mood in depression.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Jan 2022
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 31, 2022
CompletedFirst Submitted
Initial submission to the registry
February 24, 2022
CompletedFirst Posted
Study publicly available on registry
August 11, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2024
CompletedAugust 29, 2022
August 1, 2022
2.4 years
February 24, 2022
August 26, 2022
Conditions
Outcome Measures
Primary Outcomes (6)
Change in fMRI signals in thalamus region of interest (ROI) from baseline to post intervention
fMRI signal (units: %)
Through study completion (approximately 1 month)
Change in fMRI signals in amygdala ROI from baseline to post intervention
fMRI signal (units: %)
Through study completion (approximately 1 month)
Change in tasked evoked responses in amygdala ROI from baseline to post intervention
Task evoked responses in amygdala ROI (units: %)
Through study completion (approximately 1 month)
Change in cerebrospinal fluid (CSF) flow measurements from baseline to post intervention
Fluid flow measured with MRI (units: %)
Through study completion (approximately 1 month)
Change in Montgomery-Asberg Depression Rating from baseline to post intervention
Mood scores, measured on scale of 0-60
Through study completion (approximately 1 month)
Change in whole-brain voxelwise fMRI activity from baseline to post intervention
fMRI measure of hemodynamics (units: %)
Through study completion (approximately 1 month)
Secondary Outcomes (15)
Change in EEG dynamics from baseline to post intervention
Through study completion (approximately 1 month)
Change in dot probe task performance from baseline to post intervention
Through study completion (approximately 1 month)
Change in blood biomarkers of C-reactive protein from baseline to post intervention
Through study completion (approximately 1 month)
Change in blood levels of Interleukin 6 from baseline to post intervention
Through study completion (approximately 1 month)
Change in Magnetic Resonance Spectroscopy (MRS) measurement of lactate from baseline to post intervention
Through study completion (approximately 1 month)
- +10 more secondary outcomes
Study Arms (2)
Sleep deprived
EXPERIMENTALOvernight sleep deprivation
Rested
NO INTERVENTIONWell-rested sleep pattern
Interventions
Eligibility Criteria
You may qualify if:
- Adult aged 18-80
- \- Current diagnosis of major depressive disorder
You may not qualify if:
- Must not have ferrous metal implanted in head or body
- Must have no history of major head trauma
- Must not have implanted electronic devices (e.g., pacemaker, neurostimulator)
- Must not be pregnant, suspect they are pregnant, or seeking to become pregnant
- Must not be claustrophobic
- Must have no piercings or jewelry that cannot be removed
- Weight less than 250 pounds
- No lifetime history of schizophrenia or any other psychosis disorder, substantial intellectual disability, bipolar disorder, post-traumatic stress disorder or obsessive compulsive disorder
- No alcohol or substance abuse or dependence within the past 6 months
- No significant personality dysfunction
- Must not indicate significant suicide risk.
- Must not be taking medications that significantly affect sleep, psychiatric function, blood/vascular function, or anti-inflammatory medications (other than minor NSAID use).
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Boston University Charles River Campuslead
- One Mindcollaborator
- Brain & Behavior Research Foundationcollaborator
- 1907 Foundationcollaborator
Study Sites (1)
Boston University
Boston, Massachusetts, 02215, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Laura Lewis, PhD
Boston University
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- BASIC SCIENCE
- Intervention Model
- FACTORIAL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 24, 2022
First Posted
August 11, 2022
Study Start
January 31, 2022
Primary Completion
July 1, 2024
Study Completion
July 1, 2024
Last Updated
August 29, 2022
Record last verified: 2022-08